TAO WU to Aged
This is a "connection" page, showing publications TAO WU has written about Aged.
Connection Strength
0.265
-
Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3. J Am Soc Cytopathol. 2019 Jul - Aug; 8(4):206-211.
Score: 0.042
-
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Adv. 2018 09 25; 2(18):2369-2377.
Score: 0.041
-
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. Mol Cancer. 2025 Jun 11; 24(1):175.
Score: 0.016
-
TNMpBC-NeoBCSS model: a breast cancer specific survival prediction model for triple-negative metaplastic breast carcinoma patients with neoadjuvant therapy. Sci Rep. 2025 Mar 11; 15(1):8351.
Score: 0.016
-
A single-cell atlas to map sex-specific gene-expression changes in blood upon neurodegeneration. Nat Commun. 2025 Feb 25; 16(1):1965.
Score: 0.016
-
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. Cancer Commun (Lond). 2024 Dec; 44(12):1431-1443.
Score: 0.016
-
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma. Clin Cancer Res. 2024 Oct 15; 30(20):4593-4600.
Score: 0.015
-
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. Eur J Cancer. 2024 Nov; 212:114328.
Score: 0.015
-
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database. Haematologica. 2023 09 01; 108(9):2467-2475.
Score: 0.014
-
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. Am J Hematol. 2020 09; 95(9):1047-1056.
Score: 0.012
-
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021 01; 35(1):130-142.
Score: 0.011
-
Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG). Aging (Albany NY). 2019 10 06; 11(19):8463-8473.
Score: 0.011
-
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leuk Lymphoma. 2019 11; 60(11):2669-2678.
Score: 0.011
-
Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Cancer Med. 2018 12; 7(12):5952-5961.
Score: 0.010
-
Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Radiother Oncol. 2018 10; 129(1):3-9.
Score: 0.010
-
Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis. 2017 Aug 15; 16(1):155.
Score: 0.009